The UK is planning to use its Presidency of the G8 to coordinate a more international approach to dementia research.
UK annual funding on dementia research is increasing to £66 million by 2015, and President Obama has committed the US to spending around £360million ($550m) on dementia research per year. The pharmaceutical industry invests billions.
Research and investment conducted at a national level should benefit from an international dimension. Faster advances and scientific breakthrough are likely to be achieved when researchers and pharmaceutical companies collaborate more effectively and share information, resources and expertise. There is a growing body of research and data relevant to dementia collected daily throughout the world in the form of clinical and cognitive assessments, brain images and biological samples.
“Current estimates indicate 35.6 million people worldwide are living with dementia but with the world’s populations ageing, the World Health Organization estimates that number will nearly double every 20 years, to an estimated 65.7 million in 2030, and 115.4 million in 2050”.
A G8 dementia-specific summit will be held in London in September 2013 [note: this date has since moved to December 10th 2013], allowing health and science ministers, international leading experts, senior industry leaders and the Organisation for Economic Co-operation and Development (OECD) to achieve more coordination and collaboration on dementia R&D globally.
Read more: UK to use G8 to target global effort on dementia.
UK to use G8 to target global effort on dementia. London: Department of Health, May 15th 2013.
[A brief reference to this item features in Dementia and Elderly Care: the Latest Evidence Newsletter (RWNHST), Volume 3 Issue 7, May 2013].